A Phase 2 interventional study of Topotecan and Carboplatin in Sarcoma, Soft Tissue, sponsored by Cooperative Weichteilsarkom Study Group. Completed at 38 sites in Germany. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2009-04-02.
Sponsored by Cooperative Weichteilsarkom Study Group · Phase 2, Interventional, and Treatment
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin
1,668 studies on the registry are indexed under Sarcoma; 394 are open to participants now.
This study's planned enrollment of 90 is above the median of 40 across 1,283 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →This is the only study on the registry with Cooperative Weichteilsarkom Study Group as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Response according to RECIST criteria
Toxicity
Overall-Survival
Event-free-survival
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.